## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1031.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Eli Lilly (LLY) Moves Fast to Secure Lead in India's Obesity Drug Market**
- Source: Finviz | 20251230T231851 | Bullish | Relevance: 100%
- Eli Lilly (LLY) is rapidly establishing its position in India's obesity drug market, anticipating generic competition. The company has launched a social media campaign with Bollywood actors and seen its Mounjaro drug quickly become a top seller in India, surpassing competitors. Eli Lilly is also cutting prices for Mounjaro and Zepbound in Canada and the U.S. to broaden access and maintain its market lead.

**2. Comeback Town: Huntsville didn’t need UAB to win Eli Lilly — and that should terrify Birmingham**
- Source: AL.com | 20251228T141926 | Bullish | Relevance: 100%
- Huntsville secured a major Eli Lilly pharmaceutical plant investment of over $6 billion, bringing 3,450 jobs, prompting a critical look at Birmingham's economic development strategies. The article argues that Birmingham's flagship institution, UAB, lags in commercializing research, hindering the city's ability to attract similar high-value projects. It suggests Birmingham needs to prioritize true economic development over community development and foster regional cooperation, much like the state did for the Mercedes-Benz project in 1993.

**3. Total Wealth Planning LLC Grows Stock Holdings in Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251230T110832 | Bullish | Relevance: 100%
- Total Wealth Planning LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 3.0% in Q3, now holding 31,948 shares worth $24.38 million, making it their 11th-largest holding. The company reported strong Q3 earnings, beating estimates with $7.02 EPS and $17.6 billion revenue, and raised its quarterly dividend to $1.73 per share. Other institutional investors also modified their holdings, and analysts have a "Moderate Buy" rating for the stock.

**4. Novo and Lilly cut prices of weight-loss drugs in China**
- Source: Yahoo! Finance Canada | 20251230T014800 | Somewhat-Bearish | Relevance: 99%
- Novo Nordisk and Eli Lilly are reducing the prices of their weight-loss medications, Wegovy and Mounjaro, in China. Novo confirmed price adjustments for Wegovy, with reports indicating cuts of up to 48% for the highest dosages in some provinces. Eli Lilly's Mounjaro is also set to see price decreases starting January 1st, positioning both companies to compete in China's rapidly expanding market for obesity drugs.

**5. 5 Healthcare Themes for Investors to Watch in 2026**
- Source: Barron's | 20251228T080841 | Somewhat-Bullish | Relevance: 93%
- This article outlines five key healthcare themes that investors should monitor in 2026, following a period where healthcare stocks aligned with broader market performance after two years of underperformance. The growing weight-loss market, particularly with the launches of GLP-1 pills from Eli Lilly and Novo Nordisk, is highlighted as a significant transformative factor.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-12-03 | Guggenheim | $1163 | $1036 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.90M) |
| Sells | 28 ($18486.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $18486M sold (28 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 33.1x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($18486.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $967.9B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 33.1 |
| Current P/E | 45.7 |
| YoY Growth | 37.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.7% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.65% (CS: 76) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | -0.40 | Bearish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.095x | Above |
| vs SMA200 | 1.308x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1080.11
- **Stop Loss:** $1031.33 (4.5% risk)
- **Target:** $1128.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $29,162.97
- **Portfolio %:** 29.16%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*